METHODS
• A Markov health-state transition model was developed with 3-month cycles and health states based on the daily number of UIEs (Figure 1 ), with assumptions as described below
• Model cohorts were generated from available trial data (Figure 2) as follows:
-Mean number of UIEs in each health state as well as onabotA and BSC efficacy and safety were based on pooled phase 3 onabotA clinical trial data 2,3 and a long-term extension study 4 -For SNS and PTNS, efficacy and safety for both treatments were based on published literature. [5] [6] [7] [8] [9] No adverse events were assumed for PTNS
• Patients were treated with either BSC, onabotA 100U, PTNS, or SNS  BSC was defined as behavioral therapy, incontinence pads, and continued use of anticholinergic therapy in a proportion of patients, alone or rarely, in combination with catheterization  OnabotA 100U patient discontinuation rates and frequency of retreatment for each health state were derived from pooled phase 3 clinical trial data. 2-4 Discontinuation rates were 0.0%, 3.3%, 18.7%, 8.6%, 3.4%, and 4.0% for cycles 1, 2, 3, 4, 5-8, and 9-16+, respectively. Patients transitioned to BSC if they were nonresponders to treatment (<50% reduction in UIE) after 2 rounds of treatment (1 retreatment)
 PTNS patients discontinued therapy within the first 3 months or at later stage, at an average discontinuation rate of 5.4%, 5-7 and were assumed to transition to BSC without retreatment  SNS patients discontinued therapy either after initial testing (no permanent implant), at a rate of 35.2%, or after receiving a permanent implant, at a rate of 5%, 8, 9 and were assumed to transition to BSC without retreatment  Those who discontinued onabotA, PTNS, or SNS transitioned to BSC for the duration of the model
• A discount rate of 3% per year was applied to costs and outcomes
• Resource utilization, discontinuation rates, and unit cost data were obtained from published sources, reimbursement rates, and Truven MarketScan ® data ( Table 1) • Utilities were obtained from a published algorithm mapping Incontinence Quality-of-Life (I-QoL) scores to the EuroQol 5-dimensions questionnaire (EQ-5D™) 10
Base-case analysis
• The model estimates cost per quality-adjusted life-year (QALY) expressed in 2014 US dollars
• OnabotA 100U, PTNS, and SNS were compared with BSC over a 10-year time horizon
• Incremental cost-effectiveness ratios (ICER), calculated as (cost of a treatment option -BSC cost) ÷ (QALYs of a treatment option -QALYs of BSC), were used to assess cost-effectiveness of each treatment
RESULTS

Base Case
• Table 2 shows that with BSC as a comparator, onabotA had the greatest total QALYs gained and the lowest estimated ICER of any of the assessed treatments
• OnabotA dominates SNS and extendedly dominates PTNS
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Scenario Analyses (Table 3) • The model runs at 3-, 5-and 7-year time horizons demonstrated that the ICERs of onabotA and PTNS compared with BSC were below a $100,000 cost-effectiveness threshold, except for the 1-year time horizon
• In all scenarios evaluated, SNS was not cost-effective compared to BSC
• Discount rates of 6% and of 0% for both costs and QALYs and no retreatment for onabotA nonresponders scenarios had minimal impact on base-case model results
CONCLUSION
• OnabotA dominates SNS and demonstrates extended dominance over PTNS
• 
Limitations
• The model did not assess structural uncertainty. Different patient pathways and disease progression through model health states were not taken into account in the sensitivity analyses
• Variability due to heterogeneity in the patient population (systematic differences between patient subgroups) was not evaluated
• No head-to-head data were available for any of the comparators and many different data sources were used to populate the model (eg, clinical trials, observational/secondary data sources), which introduced heterogeneity and variability across treatments -However, sensitivity analyses were conducted to address uncertainty around parameter estimates • Parameter uncertainty was investigated through deterministic oneway sensitivity analyses (OWSAs) and probabilistic sensitivity analyses (PSAs)
• Model parameters were independently varied over a range determined by their 95% confidence interval where possible, or otherwise, by a plausible range of values
• A range of scenario analyses were conducted to evaluate major underlying assumptions about the patient cohort including 1-,3-, 5-, and 7-year time horizons, applying discount rates of 0% and of 6%, and not allowing retreatment for onabotA nonresponders
Sensitivity Analyses
• OWSA diagrams for onabotA, SNS, and PTNS, each versus BSC, show consistently lower ICERs for onabotA (Figure 3) • PSAs demonstrated that onabotA and PTNS had a 100% and 95.2% probability of being below a $100,000 cost-effectiveness threshold, respectively. SNS was not cost-effective in 100% of simulations (n=1000, Figure 4) • Although at low willingness to pay (WTP), BSC is preferred, the model showed high certainty that onabotA is preferred even at WTP as low as $50,000/QALY, and that PTNS and SNS are not preferred at any WTP ( Proportion of patients using anticholinergics 
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